Frontlight ResearchEarly access
Taking people in United StatesPhase 1/2
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
Key facts
- Who runs it
- Tessera Therapeutics, Inc.
- Where
- Boston, Charleston, Jacksonville, Rochester, and Seattle, United StatesSee the 5 sitesAlso in 5 other countries, 8 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 72 people, planned
- Started
- 21 Apr 2026
- Expected to end
- Mar 2029
- Type of study
- Interventional
- Treatments tested
- TSRA-196
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Males or females who are 18 to 70 years of age, inclusive, at the time of signing the informed consent
- Body mass index of 18 to 37 kg/m2, inclusive
- Confirmed diagnosis of AATD and PiZZ genotype
- At least one previous measure of blood total AAT level <11 µmol/L
- Nonsmoker for at least 6 months before screening and must remain nonsmoking for the entire study duration
- Either AAT treatment-naïve or washed out of all investigational or approved treatments that modify AAT levels for 5 half-lives or at least 4 weeks, whichever is longer, before TSRA-196 administration; Parts 1A and 2A (AATD lung disease with no or minimal liver fibrosis)
- Clinically significant lung disease, defined as 1) evidence of emphysema or bronchiectasis by computed tomography or 2) DLCO <70% of the predicted value or 3) ppFEV1 <80%
- ppFEV1 ≥35%
- METAVIR fibrosis score F0 or F1 confirmed by liver biopsy at screening, or a liver stiffness measure by FibroScan ≤7 kPa at screening
- FIB-4 index score ≤3.25 at screening
- ALT and/or AST <ULN at screening; Parts 1B and 2B (AATD liver disease with significant or severe liver fibrosis, with or without AATD lung disease)
- METAVIR fibrosis score F2 or F3 confirmed by liver biopsy at screening. A liver biopsy conducted within 12 months before screening is acceptable as a substitute
- Liver stiffness measure by FibroScan >7 and ≤15 kPa at screening
- ALT and/or AST <2 x ULN at screening
Who cannot take part
- History of one or more hospitalizations due to severe exacerbation of underlying lung disease during the year before screening or received IV antibiotics for treatment of a pulmonary infection within 6 months before screening
- Lung volume reduction surgery within 1 year before screening or plan to receive lung volume reduction surgery during the study period
- Documented chronic need for positive airway pressure therapy beyond nocturnal use
- Has received an organ transplant or is on a waiting list for an organ transplant
- Prior treatment with gene therapy using viral vectors or intended to permanently change the patient's DNA
- Any investigational products within 30 days before dosing or plan to take an investigational product before the end of study
- History of liver disease unrelated to AATD, or history of or clinical signs of cirrhosis
- Significant lung disease not attributable to manifestations of AATD, as determined by the investigator
- Seropositive for human immunodeficiency virus (HIV) (HIV-1 or HIV-2)
- Seropositive for hepatitis B (hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb] positive) with detectable HBV DNA
- Hepatitis C virus (HCV) RNA positive at screening (Parts 1A and 2A), or HCV RNA positive and/or HCV antibody positive at screening (Parts 1B and 2B)
- Presence of genetic variation in SERPINA1 gene that may disrupt the function of TSRA-196, determined by screening genotyping
- Unstable AATD-related COPD, as determined by the investigator, or severe bronchiectasis
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
Also in 5 other countries, 8 sites
- Clinical Study CenterBoston, United StatesTaking people
- Clinical Study CenterCharleston, United StatesTaking people
- Clinical Study CenterJacksonville, United StatesTaking people
- Clinical Study CenterRochester, United StatesTaking people
- Clinical Study CenterSeattle, United StatesTaking people
About the trial
What the trial wants to find out
This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver disease associated with severe alpha-1 antitrypsin deficiency (AATD)
The group in the trial
- TSRA-196 Drug ProductTreatment being tested
Treatment: TSRA-196
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated With Severe Alpha-1 Antitrypsin Deficiency
- Criteria questions
- Built from NCT07227207, who can take part
- Record updated
- 12 November 2026